We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
14
Research Clients
150
Reports published
10k+
Readers in database
Early stop of SANET-p Phase III after +ve interim analysis. Likely #surufatinib China NDA filing (2nd indication) in 2020 & potentially unique position as effective therapy across the NET (#neuroendcrinetumours) spectrum.
Read more on @HChiMed $HCM at: https://t.co/WrQb4WeQhK
#FuturaMedical £3.25m fund raise extends its cash runway, on current plans, to end-2020. Planned FDA meeting (possibly Q120) will shed further light on next steps for #DermaSys in #erectiledysfunction $FUM
https://t.co/If0GxKR8jS
Third non-exclusive collaboration for @scancellpharma 's #AvidiMab platform could generate additional value, complementing the key #ImmunoBody & #Moditope technology platforms. For more on $SCLP see: https://t.co/mZuSJRY5Vy
Key FY19 @MaxCyte_info achievements include 5 nonexclusive multiproduct #geneediting #celltherapy licences. With 8 clinical/commercial deals & pre-sales m/stones >$650m $MXCT revenue potential will soon expand beyond demand for instrument/disposables. See: https://t.co/I9vIBMeb3C
(1/2) Further ASTEROID data (#setrusumab in #osteogenesisimperfecta) show a dose-dependent stat sig bone building effect at multiple anatomical sites in adult OI patients (irrespective of subtype) $MPH.L $MREO
Global #naviciximab licence with Oncologie underlines @MereoBioPharma’s ability to strike deals, provides small boost to cash runway & retains upside, allowing the company to focus on developing its core rare disease portfolio. Read more on $MPH.L $MREO at https://t.co/LTPHitKXWa
Please sign up here to be added to our distribution database
